Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Trial details
- Registry ID
- NCT05892614
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)NCT05892614 | ATYR | Phase 2 | Recruiting | 2026-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |